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Background: The selection of treatment with early invasive procedures in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) 
should be based on risk stratification.
Methods: We evaluated the incremental value of biomarker levels for prognostication of outcomes in relation to treatments in 9,962 patients with 
NSTE-ACS randomized to ticagrelor or clopidogrel and managed in hospital with invasive (n=5,369) or noninvasive treatment (n=4,593) in the PLATO 
trial. The multivariable analyses included clinical baseline characteristics and predefined levels of high-sensitivity troponin-T (hs-TnT) (14 ng/L), NT-
proBNP (400 and 1,000 ng/L) and GDF-15 (1,200 and 1,800 ng/L). 
Results: During 6 - 12 months follow-up the rate of cardiovascular death (CVD) and spontaneous myocardial infarction (SMI) was lower with early 
invasive treatment. Hs-TnT was the only variable with a directional interaction with the effects of an invasive strategy on CVD and SMI with lower rate 
(HR 0.70, 95%CI 0.59-0.83) at hs-TnT >14ng/L but higher rate (HR 2.74, 95%CI 1.49-5.04) at hs-TnT <14 ng/L. The levels of NT-proBNP (p<0.001) 
and GDF-15 (p=0.026) were significantly related to the rate of CVD and SMI in both invasively and noni-invasively managed groups and thereby to 
the absolute benefit of invasive treatment at hs-TnT>14 ng/L. All three biomarkers contributed incrementally to the discriminative reclassification 
indexes concerning outcomes. A risk stratification tool concerning outcomes with an early invasive or noninvasive treatment based on age, diabetes 
mellitus, previous vascular disease (MI, PAD, Stroke) and these three biomarkers (C-statistic 0.72) was more effective (p<0.001) than the TIMI-NSTE 
ACS score (C-statistic 0.65) or GRACE-score (C-statistic 0.66). There was no significant interaction with the randomized medical treatment.
Conclusions: Prognostication of outcomes with an early invasive versus non-invasive treatment can be based on a stepwise process using hs-TnT, 
NT-proBNP and GDF-15 as part of a score to identify patients with different expected benefit or even harm from early invasive procedures.
